Does the media refer more to URGN or PTCT?

In the previous week, PTC Therapeutics had 5 more articles in the media than Urogen Pharma. MarketBeat recorded 7 mentions for PTC Therapeutics and 2 mentions for Urogen Pharma. PTC Therapeutics' average media sentiment score of 0.99 beat Urogen Pharma's score of -0.50 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative PTC Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MIRM or URGN?

In the previous week, Mirum Pharmaceuticals had 10 more articles in the media than Urogen Pharma. MarketBeat recorded 12 mentions for Mirum Pharmaceuticals and 2 mentions for Urogen Pharma. Mirum Pharmaceuticals' average media sentiment score of 0.82 beat Urogen Pharma's score of -0.50 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Urogen Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media prefer CNTA or URGN?

In the previous week, Urogen Pharma had 1 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 2 mentions for Urogen Pharma and 1 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.00 beat Urogen Pharma's score of -0.50 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Urogen Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media prefer COGT or URGN?

In the previous week, Cogent Biosciences and Cogent Biosciences both had 2 articles in the media. Cogent Biosciences' average media sentiment score of 0.25 beat Urogen Pharma's score of -0.50 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Urogen Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media prefer SRRK or URGN?

In the previous week, Scholar Rock had 2 more articles in the media than Urogen Pharma. MarketBeat recorded 4 mentions for Scholar Rock and 2 mentions for Urogen Pharma. Scholar Rock's average media sentiment score of 0.77 beat Urogen Pharma's score of -0.50 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Urogen Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Urogen Pharma (URGN) Competitors

$38.02 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$35.72 -2.30 (-6.05%)

As of 07/2/2026 06:57 PM Eastern

Compare

URGN vs. PTCT, MIRM, CNTA, COGT, and SRRK

Should you buy Urogen Pharma stock or one of its competitors? MarketBeat compares Urogen Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Urogen Pharma include PTC Therapeutics (PTCT), Mirum Pharmaceuticals (MIRM), Centessa Pharmaceuticals (CNTA), Cogent Biosciences (COGT), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry.

How does Urogen Pharma compare to PTC Therapeutics?

Urogen Pharma (NASDAQ:URGN) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

PTC Therapeutics has higher revenue and earnings than Urogen Pharma. PTC Therapeutics is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$140.49M	13.19	-$153.49M	-$2.75	N/A
PTC Therapeutics	$1.73B	3.99	$682.64M	-$2.33	N/A

91.3% of Urogen Pharma shares are held by institutional investors. 4.8% of Urogen Pharma shares are held by insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

PTC Therapeutics has a net margin of -22.58% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-94.83%	N/A	-62.85%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

In the previous week, PTC Therapeutics had 5 more articles in the media than Urogen Pharma. MarketBeat recorded 7 mentions for PTC Therapeutics and 2 mentions for Urogen Pharma. PTC Therapeutics' average media sentiment score of 0.99 beat Urogen Pharma's score of -0.50 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Urogen Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
PTC Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Urogen Pharma currently has a consensus target price of $39.50, indicating a potential upside of 3.89%. PTC Therapeutics has a consensus target price of $91.36, indicating a potential upside of 9.66%. Given PTC Therapeutics' higher probable upside, analysts plainly believe PTC Therapeutics is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.71

Urogen Pharma has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

Summary

PTC Therapeutics beats Urogen Pharma on 10 of the 16 factors compared between the two stocks.

How does Urogen Pharma compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Urogen Pharma (NASDAQ:URGN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

In the previous week, Mirum Pharmaceuticals had 10 more articles in the media than Urogen Pharma. MarketBeat recorded 12 mentions for Mirum Pharmaceuticals and 2 mentions for Urogen Pharma. Mirum Pharmaceuticals' average media sentiment score of 0.82 beat Urogen Pharma's score of -0.50 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Urogen Pharma has a net margin of -94.83% compared to Mirum Pharmaceuticals' net margin of -140.24%. Urogen Pharma's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Urogen Pharma	-94.83%	N/A	-62.85%

91.3% of Urogen Pharma shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 4.8% of Urogen Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Mirum Pharmaceuticals has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	14.69	-$23.36M	-$13.61	N/A
Urogen Pharma	$140.49M	13.19	-$153.49M	-$2.75	N/A

Mirum Pharmaceuticals has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market.

Mirum Pharmaceuticals presently has a consensus price target of $143.00, suggesting a potential upside of 13.86%. Urogen Pharma has a consensus price target of $39.50, suggesting a potential upside of 3.89%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Mirum Pharmaceuticals is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Urogen Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Mirum Pharmaceuticals beats Urogen Pharma on 11 of the 16 factors compared between the two stocks.

How does Urogen Pharma compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Urogen Pharma (NASDAQ:URGN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 4.1% of Centessa Pharmaceuticals shares are owned by company insiders. Comparatively, 4.8% of Urogen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Urogen Pharma had 1 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 2 mentions for Urogen Pharma and 1 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.00 beat Urogen Pharma's score of -0.50 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Urogen Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Centessa Pharmaceuticals has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Urogen Pharma	-94.83%	N/A	-62.85%

Centessa Pharmaceuticals presently has a consensus target price of $41.33, indicating a potential upside of 2.06%. Urogen Pharma has a consensus target price of $39.50, indicating a potential upside of 3.89%. Given Urogen Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Urogen Pharma is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Urogen Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Centessa Pharmaceuticals has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market.

Urogen Pharma has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A
Urogen Pharma	$140.49M	13.19	-$153.49M	-$2.75	N/A

Summary

Urogen Pharma beats Centessa Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Urogen Pharma compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Urogen Pharma (NASDAQ:URGN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

In the previous week, Cogent Biosciences and Cogent Biosciences both had 2 articles in the media. Cogent Biosciences' average media sentiment score of 0.25 beat Urogen Pharma's score of -0.50 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Urogen Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Cogent Biosciences has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Urogen Pharma	-94.83%	N/A	-62.85%

Urogen Pharma has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Urogen Pharma	$140.49M	13.19	-$153.49M	-$2.75	N/A

91.3% of Urogen Pharma shares are held by institutional investors. 6.6% of Cogent Biosciences shares are held by insiders. Comparatively, 4.8% of Urogen Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cogent Biosciences currently has a consensus price target of $43.73, indicating a potential upside of 13.02%. Urogen Pharma has a consensus price target of $39.50, indicating a potential upside of 3.89%. Given Cogent Biosciences' higher possible upside, research analysts clearly believe Cogent Biosciences is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Urogen Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Cogent Biosciences has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market.

Summary

Cogent Biosciences beats Urogen Pharma on 8 of the 14 factors compared between the two stocks.

How does Urogen Pharma compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Urogen Pharma (NASDAQ:URGN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Scholar Rock presently has a consensus target price of $56.00, indicating a potential upside of 2.04%. Urogen Pharma has a consensus target price of $39.50, indicating a potential upside of 3.89%. Given Urogen Pharma's higher probable upside, analysts plainly believe Urogen Pharma is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Urogen Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Scholar Rock has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market.

In the previous week, Scholar Rock had 2 more articles in the media than Urogen Pharma. MarketBeat recorded 4 mentions for Scholar Rock and 2 mentions for Urogen Pharma. Scholar Rock's average media sentiment score of 0.77 beat Urogen Pharma's score of -0.50 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Scholar Rock has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Urogen Pharma	-94.83%	N/A	-62.85%

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 13.3% of Scholar Rock shares are held by company insiders. Comparatively, 4.8% of Urogen Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Urogen Pharma has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Urogen Pharma	$140.49M	13.19	-$153.49M	-$2.75	N/A

Summary

Urogen Pharma beats Scholar Rock on 9 of the 16 factors compared between the two stocks.

Get Urogen Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding URGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

URGN vs. The Competition

Export

Metric	Urogen Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.85B	$3.78B	$7.18B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.51%
P/E Ratio	-13.83	21.61	28.02	24.70
Price / Sales	13.19	331.74	535.36	97.93
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	-16.90	8.66	10.96	6.46
Net Income	-$153.49M	$23.81M	$3.57B	$337.01M
7 Day Performance	10.08%	3.39%	2.12%	1.69%
1 Month Performance	41.60%	10.81%	5.25%	3.81%
1 Year Performance	181.84%	62.61%	33.29%	23.90%

Urogen Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
URGN Urogen Pharma	1.8835 of 5 stars	$38.02 flat	$39.50 +3.9%	+181.8%	$1.85B	$140.49M	N/A	200
PTCT PTC Therapeutics	3.0937 of 5 stars	$84.41 +2.8%	$91.36 +8.2%	+70.8%	$6.81B	$1.73B	N/A	1,410	Insider Trade
MIRM Mirum Pharmaceuticals	2.3426 of 5 stars	$114.77 +3.3%	$139.80 +21.8%	+151.5%	$6.77B	$521.31M	N/A	140	News Coverage Analyst Forecast Insider Trade Gap Down
CNTA Centessa Pharmaceuticals	1.1293 of 5 stars	$40.71 +0.5%	$41.33 +1.5%	N/A	$6.27B	$15M	N/A	200	Short Interest Decrease High Trading Volume
COGT Cogent Biosciences	1.4534 of 5 stars	$37.53 +3.4%	$43.73 +16.5%	+408.1%	$6.20B	N/A	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:URGN) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Urogen Pharma (URGN) Competitors

URGN vs. PTCT, MIRM, CNTA, COGT, and SRRK

How does Urogen Pharma compare to PTC Therapeutics?

Summary

How does Urogen Pharma compare to Mirum Pharmaceuticals?

Summary

How does Urogen Pharma compare to Centessa Pharmaceuticals?

Summary

How does Urogen Pharma compare to Cogent Biosciences?

Summary

How does Urogen Pharma compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN vs. The Competition

Urogen Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Urogen Pharma (URGN) Competitors

URGN vs. PTCT, MIRM, CNTA, COGT, and SRRK

How does Urogen Pharma compare to PTC Therapeutics?

Which has higher valuation and earnings, URGN or PTCT?

Do institutionals & insiders believe in URGN or PTCT?

Is URGN or PTCT more profitable?

Does the media refer more to URGN or PTCT?

Do analysts prefer URGN or PTCT?

Which has more risk and volatility, URGN or PTCT?

Summary

How does Urogen Pharma compare to Mirum Pharmaceuticals?

Does the media favor MIRM or URGN?

Is MIRM or URGN more profitable?

Do institutionals and insiders have more ownership in MIRM or URGN?

Which has better valuation & earnings, MIRM or URGN?

Which has more volatility and risk, MIRM or URGN?

Do analysts prefer MIRM or URGN?

Summary

How does Urogen Pharma compare to Centessa Pharmaceuticals?

Do insiders and institutionals believe in CNTA or URGN?

Does the media prefer CNTA or URGN?

Is CNTA or URGN more profitable?

Do analysts recommend CNTA or URGN?

Which has more risk and volatility, CNTA or URGN?

Which has better earnings & valuation, CNTA or URGN?

Summary

How does Urogen Pharma compare to Cogent Biosciences?

Does the media prefer COGT or URGN?

Is COGT or URGN more profitable?

Which has better valuation and earnings, COGT or URGN?

Do insiders & institutionals believe in COGT or URGN?

Do analysts rate COGT or URGN?

Which has more risk and volatility, COGT or URGN?

Summary

How does Urogen Pharma compare to Scholar Rock?

Do analysts rate SRRK or URGN?

Which has more volatility and risk, SRRK or URGN?

Does the media prefer SRRK or URGN?

Is SRRK or URGN more profitable?

Do insiders and institutionals believe in SRRK or URGN?

Which has preferable earnings & valuation, SRRK or URGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN vs. The Competition

Urogen Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools